Showing results (321-330 of 793) with videos related to
Sort By:
Pageof 80
American Journal of Hematology|July 24, 2010
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.Journal of Blood Medicine|September 2, 2017
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomibPaul G Richardson, Shaji Kumar, Jacob P Laubach, et al.Leukemia & Lymphoma|October 7, 2014
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agentsMorie A Gertz, Evangelos Terpos, Angela Dispenzieri, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2010
Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition diseaseElizabeth C Lorenz, Sanjeev Sethi, Tanya L Poshusta, et al.Blood|October 22, 2024
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detectionAlissa Visram, Dirk Larson, Aaron Norman, et al.Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin LymphomaJonathon B Cohen, Silvana Bucur, Elliott F Winton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding studySagar Lonial, Jonathan Kaufman, Mourad Tighiouart, et al.Cancer|November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaAjai Chari, Sagar Lonial, Tomer M Mark, et al.Blood Cancer Journal|May 19, 2019
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathiesShaji Kumar, Dirk R Larson, Angela Dispenzieri, et al.Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.Pageof 80